DiaMedica Therapeutics Inc.
DMAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401040
No open-market purchases or sales by DiaMedica Therapeutics Inc. insiders were filed in the last 90 days; 88 institutions reported holding it in 13F filings for Q2 2026, worth $87.8M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding DiaMedica Therapeutics Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 32 | 32 | 0 |
| Shares | 4.60M | 5.06M | +464.0K (+10.1%) |
| Value | $12.7M | $14.9M | +$2.20M (+17.3%) |
New holders (3)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| LPL Financial LLC | 17,500 | $51.6K | 0.00% |
| Magnolia Capital Advisors LLC | 10,000 | $29.5K | 0.02% |
| Bank of America Corp | 183 | $540 | 0.00% |
Sold out (3)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Bank of New York Mellon Corp | 24,000 | $66.5K |
| UBS Group AG | 1,926 | $5.33K |
| Wells Fargo & Company | 175 | $485 |